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Outer membrane vesicles from 
flagellin-deficient Salmonella 
enterica serovar Typhimurium 
induce cross-reactive immunity and 
provide cross-protection against 
heterologous Salmonella challenge
Qiong Liu1,2,3,*, Qing Liu1,*, Jie Yi1, Kang Liang1, Bo Hu4, Xiangmin Zhang5, Roy Curtiss III2 & 
Qingke Kong1,2
Outer membrane vesicles (OMVs) isolated from Salmonella Typhimurium are potentially useful for 
developing subunit vaccines because of high immunogenicity and protective efficacy. However, 
flagella might remain in OMV pellets following OMV purification, resulting in non-essential immune 
responses and counteraction of bacterial protective immune responses when developing a vaccine 
against infection of multiple serotypes Salmonella. In this study, a flagellin-deficient S. Typhimurium 
mutant was constructed. Lipopolysaccharide profiles, protein profiles and cryo-electron microscopy 
revealed that there were no significant differences between the wild-type and mutant OMVs, with the 
exception of a large amount of flagellin in the wild-type OMVs. Neither the wild-type OMVs nor the non-
flagellin OMVs were toxic to macrophages. Mice immunized with the non-flagellin OMVs produced high 
concentrations of IgG. The non-flagellin OMVs elicited strong mucosal antibody responses in mice when 
administered via the intranasal route in addition to provoking higher cross-reactive immune responses 
against OMPs isolated from S. Choleraesuis and S. Enteritidis. Both intranasal and intraperitoneal 
immunization with the non-flagellin OMVs provided efficient protection against heterologous  
S. Choleraesuis and S. Enteritidis challenge. Our results indicate that the flagellin-deficient OMVs 
may represent a new vaccine platform that could be exploited to facilitate the production of a broadly 
protective vaccine.
Facultative intracellular pathogenic Salmonella spp. cause gastroenteritis and enteric fever, posing a haz-
ard to human health and resulting in economic losses in animal industries1,2. With the emergence of multiple 
drug-resistant Salmonella strains, vaccination has begun to play an important role in controlling and preventing 
Salmonella infections around the world1,3. Killed vaccines and subunit vaccines of Salmonella provide short-term 
immunity and have been used with the variable efficacy, while attenuated live vaccines are associated with the 
potential risk of substantial infectivity in immunocompromised and elderly patients4. The ideal vaccine should 
fulfill a number of criteria, including protective efficacy and safety5.
Outer membrane vesicles (OMVs) are naturally produced by Gram-negative bacteria, such as Escherichia coli6, 
Salmonella7, Helicobacter pylori8 and Neisseria meningitidis9, and OMVs-like membrane vesicles are produced by 
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Gram-positive bacteria, such as Clostridium perfringens10. OMVs range in average size from 20 nm to 500 nm. 
Additionally, OMVs from Gram-negative bacteria have a structure with a spherical bilayer membrane that con-
tains biologically active components, such as membrane proteins and lipopolysaccharide (LPS). OMVs perform 
diverse biological functions, including the secretion and mediation of factors that contribute to bacterial patho-
genicity11. LPS and outer membrane proteins (OMPs) contained in the OMVs may serve as adjuvants of immune- 
stimulating molecules to potently stimulate professional antigen-presenting cells (APCs) and thereby enhance 
immune responses7. OMVs are potential candidate targets for developing subunit vaccines and vaccine carriers 
because of their high immunogenicity and efficiency, lack of ability to infect hosts and their ability to deliver 
heterologous antigens12,13. A vaccine based on OMVs obtained from N. meningitidis that contains three highly 
immunogenic proteins has been approved for use in Europe in individuals over 2 months old14.
Following OMV purification, the OMV pellet can contain large macro-molecules, such as flagellin15. Flagellin, 
the structural protein contained in bacterial flagella, is common in pathogenic and commensal bacteria such 
as Salmonella and E. coli16,17. Flagellated Salmonella, which retain motility, can express two genetically distinct 
flagellin proteins, called phase 1 and phase 2 flagellin, which are encoded by the fliC and fljB genes, respectively18. 
The function of Salmonella flagella depends on the assembly of two monomeric flagellin proteins into a larger 
flagella polymer16. Salmonella flagellin elicits pro-inflammatory responses to epithelia through interactions with 
Toll-like receptor 5 (TLR5). The activation of TLR5 mobilizes nuclear factor (NF)-κ B and induces the production 
of tumour necrosis factor-α (TNF-α )19. Therefore, flagellin is often used as an adjuvant in vaccines, in which the 
corresponding flagellin is engineered to display a foreign peptide on the surface, fused with foreign proteins, or 
chemically linked to bacterial polysaccharides20–22.
Flagellin acts as a good protective antigen because it is capable of providing protection against bacterial infec-
tion23,24. The presence of large amounts of flagellin in OMVs may interfere with the immunogenicity of other anti-
gens or induce excessive pro-inflammatory responses as a result of the characteristics of the immune-stimulating 
molecule16,25. In this study, we analysed LPS profiles and identified proteins that were contained in OMVs puri-
fied from both a wild-type strain and a non-flagellin mutant. We then evaluated the structure of the purified 
OMVs using cryo-electron microscopy (EM). We also evaluated the immunogenicity and protective efficacy 
of the OMVs when administered via different routes of immunization. We demonstrated that the non-flagellin 
OMVs induced strong mucosal and systemic responses and provided effective protection against challenge with 
diverse Salmonella serovars.
Materials and Methods
Bacterial strains, plasmids and growth conditions. All strains and plasmids used in this study are 
listed in the Table 1. S. Typhimurium and E. coli were grown in Luria-Bertani (LB) broth or agar (Difco, Detroit, 
MI, USA) at 37 °C. LB agar containing 5% sucrose was used for sacB gene-based counter-selection during the 
construction of the mutant strain26. Diaminopimelic acid (DAP) (50 μ g/ml) was added to the growth medium 
used for the ∆ asd strains27. All experimental protocols were approved by Sichuan Agricultural University and 
Arizona State University.
The primers used in this study are listed in Table 2. DNA manipulations were performed as previously 
described28. E. coli were transformed using electroporation. Transformants were selected on LB agar plates con-
taining the appropriate antibiotics. For construction of the ∆ fliC mutation, two pairs of primers, fliC-1F/fliC-1R 
and fliC-2F/fliC-2R, were used to amplify approximately 300 bp upstream and downstream fragments of the 
gene fliC, respectively, from χ 3761 (wild-type S. Typhimurium), and then the two fragments were joined by PCR 
using the primers fliC-1F/fliC-2R. The resulting PCR product had a terminal base A when using LA Taq enzyme 
Strain or Plasmid Description Source
Strains
S. Typhimurium
χ 3761 S. Typhimurium UK-1 64
K081 ∆ fliC12 χ 3761
K082 ∆ fljB15 χ 3761
K083 ∆ fliC12 ∆ fljB15 K081
S100 S. Typhimurium, clinical isolate from duck 42
S246 S. Enteritidis, clinical isolate from chicken 42
S340 S. Choleraesuis, clinical isolate from pig 42
E. coli
χ 7232 endA1 hsdR17 (rK−, mK+) supE44 thi-1 recA1 gyrArelA1Δ (lacZYA-argF) U169λ pirdeoR (ϕ 80dlac Δ (lacZ ) M15) 65
χ 7213 thi-1 thr-1 leuB6 glnV44 tonA21 lacY1 recA1 RP4-2-Tc :: μ λ pir Δ asdA4 Δ zhf-2 :: Tn 10 65
Plasmids
pYA4278 Suicide vector, sacB mobRP4 oriR6K Cmr 26
pQK256 For deletion of fliC This study
pQK257 For deletion of fljB This study
Table 1.  Bacterial strains and plasmids used in this study.
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(TaKaRa, Otsu, Japan), and it was then inserted to the T-terminal pYA4278 vector generated by AhdI digestion. 
This approach created the suicide plasmid pQK256 for fliC deletion. The same strategy was used to construct 
pQK257 for fljB gene deletion. ∆ fliC and ∆ fljB mutations were introduced into S. Typhimurium by a suicide 
plasmid method, generating mutant K8329.
Purification and characteristics of OMVs. Unless otherwise specified, the OMVs described in this study 
are native OMVs (nOMVs) without any detergent processing, and isolated from Salmonella UK-1 and its mutants 
according to previously described methods13. Cryo-EM was used as previously described to evaluate the shapes 
of the purified OMVs30. The protein concentration in the OMVs was used to indicate OMV concentration in the 
following experiments. The protein concentration of the OMVs was measured using a bicinchoninic acid (BCA) 
assay (Thermo Pierce, Rockford, IL, USA), and 10 μ g of each OMV sample, based on protein content, was ana-
lysed using SDS-PAGE and stained using GelCodeTM Blue Stain Reagent (Thermo Pierce, Rockford, IL, USA).
The LPS profiles of the OMVs were examined using standard methods31. The OMV samples were separated 
on 12% sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) gels and then visualized using 
silver staining. The quantification of LPS content in the same amount of each OMV sample (50 μ g) was measured 
via Kdo (3-deoxy-D-manno-octulosonic acid) analysis. S. Typhimurium LPS (Sigma-Aldrich, Saint Louis, MO, 
USA) was used as the standard32.
For the LC-MS/MS analyses, each protein lane in the gel was cut into five slices, and each slice was then 
cut into 1 mm cubes. The procedures that were subsequently followed in these assays are described in a previ-
ous study33. Raw MS files were searched against S. Typhimurium LT2 in the Uniprot database (downloaded on 
February 14, 2016) using MaxQuant software. The precursor mass tolerance was set to 7 ppm. The fragment ion 
mass tolerance was set to 0.5 Da.
Assays of OMV uptake and cytotoxicity assay in cell lines. OMVs were labeled and incubated with 
the 1% (vol/vol) lipophilic fluorophore dialkylcarbocyanine iodide (Dil) (Invitrogen, Grand Island, NY, USA) 
for 30 min at 37 °C. The OMV suspensions were ultracentrifuged (150,000 × g, 4 °C, 2 h) and washed three times 
with DPBS. Labeled OMV particles were pelleted in DPBS and determined the protein concentration to 2 mg/ml 
solutions by BCA protein assay kit (Thermo Pierce, Rockford, IL, USA) for use.
Murine macrophage RAW264.7 cells were maintained at 37 °C with 5% CO2 in DMEM (Gibco BRL, Grand 
Island, NY, USA) containing 10% FBS (Hyclone, Logan, UT, USA). Cells were plated onto the wells of a 24-well 
plate (5 × 105 cells per well) covered with glass coverslips (Biokeystone, CA, USA) and cultured for 24 h. After 
three washed with PBS, labeled OMVs were added into culture medium at final concentration of 2 μ g/ml. After 
culturing for 2 h, cells were washed three times with PBS and then fixed with 4% formaldehyde in PBS for 10 min, 
and later cells incubated with OMVs were blocked with SEA block buffer (Thermo Pierce, Rockford, IL, USA) 
for 1 h at room temperature. Nuclei were labeled with 4′ , 6-diamidino-2-phenylindole (DAPI) (Invitrogen, 
Grand Island, NY, USA) for 30 min in room temperature. Cells were visualized with AMG EVOS digital inverted 
multi-functional microscope (Advanced Microscopy Group, Bothell, WA, USA) at 100 × magnification.
To investigate the cytotoxicity of OMVs for macrophages, diverse concentrations of OMVs ranging from 
3.075 μ g/ml to 100 μ g/ml were added to RAW264.7 cells plated in 24-well plates (5 × 105 cells/well). After 24 hours, 
the supernatants from each well were collected and evaluated by a Multitox-Fluor Multiplex Cytotoxicity Assay 
(Promega, Madison, WI, USA) according to the manufacturer’s instructions. All experiments were performed in 
triplicate.
Ethic statement. All experiments involving animals were conducted in compliance with the Animal Welfare 
Act and related regulations of Sichuan Agricultural University related to animal experiments (Ya’an, China; 
Approval No. 2011-028). All animal works were approved by the committee of Sichuan Agricultural University. 
The principles stated in the Guide for the Care and Use of Laboratory Animals were followed. All efforts were 
made to minimize animal suffering during the experiments.
Immunization and challenges in animal experiments. Female BALB/c mice (6 weeks old, 16–22 g) 
were purchased from the Dashuo Biotechnology Co., Ltd. (Chengdu, China). Mice were divided into groups of 5 
or 6 and then intranasally immunized with 20 μ g of OMVs suspended in 10 μ l of Dulbecco’s Phosphate Buffered 
Saline (DPBS) buffer. Intraperitoneal immunizations were performed using 5 μ g of OMVs suspended in 100 μ l 
DPBS buffer. The intranasal administration of 10 μ l of DPBS buffer or the intraperitoneal administration of 100 μ l 
Primer Sequence (5′-3′) Function
fliC-1F CGTTCTTTGTCAGGTCTGTC For deletion of
fliC-1R GATTAGCGGCCGCGATCTTTTCCTTATCAATTA fliC by suicide
filC-2F AAGATCGCGGCCGCTAATCCGGCGATTGATTCAC plasmid
filC-2R TGTACCCGGCACAGACGGTC
fljB-1F AGTGAGCTCCACGTTCATGT For deletion of
fljB-1R AATTAGCGGCCGCAAAATTTTCCTTTTGGAAGG fljB by suicide
fljB-2F ATTTTGCGGCCGCTAATTTATTTCGTTTTATTC plasmid
fljB-2R GTCATTACCTGATAATTCTTC
Table 2.  Primers used in this study.
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of DPBS buffer served as the negative controls for the respective immunization experiments. Booster immuni-
zations were then given administered at 4 weeks after the first immunization. Blood samples were collected via 
orbital sinus puncture, and vaginal secretions were collected by repeatedly flushing the animals using 0.1 ml PBS 
buffer at intervals of two weeks. Following centrifugation, soluble fractions of sera and secretion samples were 
harvested and stored at − 80 °C for future use. Five weeks after a booster immunization, the mice were challenged 
via an oral route with a lethal dose of the wild-type Salmonella strain in 20 μ l of PBS with 0.01% gelatin (BSG 
buffer). The challenged mice were monitored daily for 30 days. The animal experiments were performed twice, 
and the data were combined for analysis.
Enzyme-linked immunosorbent assay (ELISA). S. Typhimurium LPS was purchased from 
Sigma-Aldrich Company (Saint Louis, MO, USA). OMPs were isolated from Salmonella as previously described34. 
UniProt accession MW (kDa)* Protein name Subcellular localization Intensity** Matched peptides
OMVs isolated from flagellin-deficient Salmonella
O30916 61.934 Inositol phosphate phosphatase (SopB) Periplasmic 1.42E + 10 63
P0CL52 73.941 Cell invasion protein (SipA) Extracellular 1.23E + 10 68
P0CL47 42.983 Cell invasion protein (SipC) Extracellular 1.16E + 10 39
P02936 37.515 Outer membrane protein A (OmpA) Outer Membrane 9.83E + 09 24
P0A263 41.238 Outer membrane protein C (OmpC) Outer Membrane 7.12E + 09 26
P37592 39.679 Outer membrane porin protein (OmpD) Outer Membrane 7.05E + 09 22
Q56019 62.45 Cell invasion protein (SipB) Extracellular 4.49E + 09 39
Q7CQN4 8.3914 Major outer membrane lipoprotein 1 (Lpp1) Outer Membrane 4.00E + 09 7
P16328 49.834 Flagellar hook-associated protein 2 (FliD) Extracellular 3.93E + 09 43
P02941 59.613 Methyl-accepting chemotaxis protein II (Tar) Cytoplasmic Membrane 2.59E + 09 27
Q7CP97 65.491 Fumarate reductase flavoprotein subunit (FrdA) Cytoplasmic Membrane 1.55E + 09 34
P26466 50.548 Maltoporin (LamB) Outer Membrane 1.55E + 09 20
P0A1J5 59.109 Flagellar hook-associated protein 1 (FlgK) Extracellular 1.53E + 09 35
Q8ZRP0 89.525 Outer membrane protein assembly factor (BamA) Outer Membrane 1.52E + 09 49
Q8ZLZ4 53.685 Outer membrane channel (TolC) Outer Membrane 1.48E + 09 27
Q7CQW9 18.865 Tol protein required for outer membrane integrity (Pal) Outer Membrane 1.44E + 09 8
P0A1× 0 15.547 Outer membrane lipoprotein (SlyB) Outer Membrane 1.33E + 09 10
P35672 61.795 Protein (InvG) Outer Membrane 1.10E + 09 37
Q8ZQT5 46.148 Protein (TolB) Periplasmic 1.09E + 09 20
Q7CQP6 27.992 Scaffolding protein for murein-synthesizing holoenzyme (MipA) Outer Membrane 1.02E + 09 11
OMVs isolated from the wild-type Salmonella
P06179 51.611 Flagellin (FliC) Extracellular 1.33E + 10 48
P0CL47 42.983 Cell invasion protein SipC Extracellular 8.83E + 09 35
P0CL52 73.941 Cell invasion protein SipA Extracellular 5.01E + 09 61
Q56019 62.45 Cell invasion protein SipB Extracellular 3.66E + 09 45
P52616 52.535 Phase 2 flagellin (FljB) Extracellular 3.33E + 09 40
P16328 49.834 Flagellar hook-associated protein 2 (FliD) Extracellular 2.12E + 09 38
P0A263 41.238 Outer membrane protein C (OmpC) Outer Membrane 1.67E + 09 21
Q7CQD4 26.448 Guanine nucleotide exchange factor (SopE2) Extracellular 1.19E + 09 16
P74873 60.047 Secreted effector protein (SptP) Extracellular 9.38E + 08 31
Q8ZQC8 37.782 Secreted effector protein (SopD2) Cytoplasmic 7.07E + 08 17
Q56026 37.112 Cell invasion protein (SipD) Extracellular 6.88E + 08 24
P16326 34.175 Flagellar hook-associated protein (FlgL) Extracellular 6.56E + 08 21
P02936 37.515 Outer membrane protein A (OmpA) Outer Membrane 6.40E + 08 19
Q8ZNR3 86.782 E3 ubiquitin-protein ligase (SopA) Periplasmic 6.00E + 08 36
P37592 39.679 Outer membrane porin protein (OmpD) Outer Membrane 5.76E+ 08 16
Q7CQW9 18.865 Tol protein required for outer membrane integrity (Pal) Outer Membrane 1.41E + 08 8
Q7CQVB 18.494 Outer membrane protease, receptor for phage (OmpX) Outer Membrane 1.41E + 08 11
Q93GL9 26.169 Conjugative transfer: surface exclusion (TraT) Outer Membrane 8.42E + 08 7
Q8ZP50 22.958 Outer membrane protein (OmpW) Outer Membrane 7.44E + 08 5
Q7CQP6 27.992 Scaffolding protein for murein-synthesizing holoenzyme (MipA) Outer Membrane 7.44E + 08 11
Table 3.  Major proteins identified from flagellin-deficient and wild-type OMVs. *The values represented as 
MW (kDa) indicate the calculated molecular weight of the identified proteins. **This table lists the 20 proteins 
with the highest abundance that were identified in the flagellin-deficient and wild-type OMVs in the end 
arrangement.
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Quantitative ELISA was used to analyse antibody levels. Briefly, solutions containing 2 μ g of Salmonella OMPs or 
1 μ g of Salmonella LPS per well were suspended in 100 μ l of sodium carbonate-bicarbonate coating buffer (pH 9.6) 
and used to coat NUNC MaxiSorpTM 96-well plates (Thermo Scientific, Waltham, MA, USA). The plates were 
then incubated overnight at 4 °C. To obtain standard curves for each antibody isotype, plates were coated in 
triplicate with two-fold dilutions of the appropriate purified mouse Ig isotype standard IgG, IgG1, IgG2a and IgA 
(BD Biosciences, San Jose, CA, USA), starting at 0.5 μ g/μ l. The plates were washed 3 times with PBST (PBS with 
0.1% Tween 20) and then blocked with a 2% bovine serum albumin (BSA) solution for 2 h at room temperature. 
A 100 μ l volume of suitably diluted sample was added in triplicate to the individual wells, and the plates were 
incubated for 1 h at room temperature. After washing the wells with PBST, biotinylated goat anti-mouse IgG, IgG1, 
IgG2a and anti-IgA (Southern Biotechnology Inc., Birmingham, AL) was added to each well. The wells were then 
developed using a streptavidin-alkaline phosphatase conjugate (Southern Biotechnology, Inc., Birmingham, AL), 
and colour was detected using p-nitrophenylphosphate substrate (Sigma-Aldrich, St. Louis, MO, USA) in dietha-
nolamine buffer (pH 9.8). Colour development (absorbance) was read at 405 nm using an automated ELISA plate 
Figure 1. Characterization, visualization and cytotoxicity of OMVs derived from S. Typhimurium and 
non-flagellin mutant strain. (a) Cryo-EM imaging of OMVs. OMVs derived from the flagellin-deficient  
S. Typhimurium were visualized using cryo-EM. The red arrows indicate the visible OMVs. (b) In total, 10 μ g of 
OMVs from each sample was subjected to 12% SDS-PAGE and stained with GelCodeTM Blue Stain. The major 
OMPs, including OmpA, OmpC/F and OmpD, are marked on the left, and the flagellar FliC and FljB proteins 
are labelled on the right. (c) LPS profiles from OMVs. LPS obtained from OMVs was visualized using silver 
staining after the samples were separated using 12% SDS-PAGE. (d) Quantification of LPS levels in OMVs.  
The same amount of OMVs (50 μ g) was measured using a Kdo (3-deoxy-D-manno-octulosonic acid) analysis.  
S. Typhimurium LPS was used as the standard. (e) The cytotoxicity of OMVs derived from S. Typhimurium 
and the flagellin-deficient mutant in RAW264.7 macrophage cells. Cells were incubated with the corresponding 
OMVs at the indicated dose. Cell viability was determined by measuring the fluorescence in the supernatants 
using a Multitox-Fluor Multiplex Cytotoxicity Assay. Supernatants from cells without OMVs and cell lysis 
solution were treated to induce cell lysis, and these products were used as the negative and positive controls, 
respectively. Two-way ANOVA was performed to determine the significance of differences.
www.nature.com/scientificreports/
6Scientific RepoRts | 6:34776 | DOI: 10.1038/srep34776
reader (Bio-Rad iMark Microplate Reader, USA) after the appropriate incubation period. The final Ig isotype 
concentration in samples was calculated using appropriate standard curves, and a log-log regression curve was 
calculated from at least four dilutions of the isotype standards.
To confirm cross-reactivity between the OMVs from the flagellin-deficient mutant, serum IgG antibodies 
against OMPs from the heterologous serotypes S. Choleraesuis and S. Enteritidis were detected using competitive 
ELISA35. 2 μ g per well of S. Typhimurium OMPs as the coated antigen were incubated in plates, and a 100 μ l vol-
ume of 50-fold diluted serum sample was added to each well. After 1 h of incubation at room temperature, diluted 
S. Choleraesuis or S. Enteritidis OMPs as the competitive antigen (dilutions from 10-fold to 7,290-fold) were incu-
bated in wells for 2 h at 37 °C. The next procedures were following our standard methods previously described. 
The absorbance at 405 nm was read in an automated ELISA plate (Bio-Rad iMark Microplate Reader, USA).
Statistical analysis. One-way or two-way analysis of variance (ANOVA) was performed to determine 
the significance of differences between the mean values of the experimental and control groups. The data are 
expressed as the means ± standard deviations. The means were compared using the least significant difference 
test. The differences in survival rates among all groups were analysed using the log-rank sum test. P < 0.05 was 
considered a slight significant difference. All data were analysed statistically using the Graph-Pad Prism 5 soft-
ware package (Graph Software, San Diego, CA, USA)36.
Results
Purification, characterization and visualization of OMVs. Three mutant strains, K081 (∆ fliC12), 
K082 (∆ fljB15) and K083 (∆ fliC12 ∆ fljB15), and the wild-type strain S. Typhimurium χ 3761 were used to purify 
OMVs (Table 1). Cryo-EM was used to evaluate the structure of the OMVs. OMVs purified from the mutant 
∆ fliC12 ∆ fljB15 were spherical with a bilayer membrane, and no flagellin was visible (Fig. 1a). A large number of 
flagellin polymers were observed in the OMVs that were isolated from the wild-type strain, but the OMVs were 
still visible (Fig. S1).
Purified OMVs were analysed using SDS-PAGE and stained using GelCodeTM Blue Stain Reagent (Fig. 1a). 
Bands corresponding to both phase 1 and 2 flagellin were observed at approximately 50 kDa in the OMVs 
obtained from wild-type S. Typhimurium, while no bands corresponding to flagellin proteins were observed in 
the OMVs from the flagellin-deficient mutant. The major Salmonella OMPs OmpA, OmpD and OmpC/F were 
observed in all of the OMVs (Fig. 1). The MS analysis was also consistent with this result (Table 3). Among the 
proteins that were identified using MS, we also observed other effector proteins, such as SipABC and SopB in both 
of the OMV samples in addition to a large amount of OmpACD (Table 3). The LPS profiles and the quantifica-
tion of the OMVs that were purified from the wild-type strain and its derivatives were also determined, and no 
obvious differences were observed following silver staining (Fig. 1c) or in a quantitative assay based on the Kdo 
method (Fig. 1d).
Figure 2. Internalization of OMVs by RAW264.7 macrophage cells. OMVs (2 μ g/ml final concentration) 
were incubated with cells for 12 hours. OMVs were stained by 1% (vol/vol) lipophilic fluorophore 
dialkylcarbocyanine iodide (Dil) (red), and the nuclei (blue) were stained by DAPI. The results were recorded 
using an AMG EVOS digital inverted multi-functional microscope (AMG) at 100x magnification. Arrows 
indicate the internalization of OMVs derived from S. Typhimurium by macrophages.
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Cytotoxic effects of OMVs in macrophages. To explore the effects of the OMVs on cell viability, we 
examined cytotoxicity in cells treated with the OMVs for 24 hours. Both the flagellin-deficient OMVs and 
the wild-type OMVs showed gradual cell lysis when inoculated with increased concentration ranging from 
3.075 μ g/ml to 100 μ g/ml. The data showed that the viability of cells treated with the non-flagellin OMVs and with 
the wild-type OMVs did not have any significant difference regardless of the concentration of treated OMVs, 
indicating that the flagellin in the wild-type OMVs elicited only a mild level of cytotoxic activity (Fig. 1e)16,37.
Uptake assay of OMVs in macrophages. As secretory vehicles for bacterial proteins and lipids, OMVs 
play critical roles in establishing colonization, transmitting virulence factors into host cells, and modulating 
host cell responses11,38. We determined the uptake of OMVs from the wild-type strain and the non-flagellin 
mutant by RAW264.7 macrophages. Microscopy analysis indicated that OMVs from the wild-type strain and the 
non-flagellin mutant strain were observed around the nucleus (blue), indicating that OMVs could be internalized 
by macrophages (Fig. 2), and the uptake of the different strains did not show obvious differences.
OMVs elicit strong humoral and mucosal immune responses. To explore the immunogenicity of 
the OMVs from the flagellin-deficient mutant strain, groups of 6 mice each were intranasally or intraperitone-
ally immunized with the corresponding OMVs (20 μ g in 10 μ l DPBS or 5 μ g in 100 μ l DPBS, respectively). After 
immunization, all of the animals that were immunized via the intraperitoneal or intranasal route remained in 
good health and exhibited no abnormal behaviour.
Quantitative ELISA was used to determine the levels of antibodies in the sera and vaginal washes that were 
obtained from the immunized mice. The results showed that the serum anti-LPS or anti-OMP IgG levels in 
the mice that were immunized intraperitoneally or intranasally with OMVs represented significantly higher 
Figure 3. IgG and secretory IgA (S-IgA) immune responses were analysed in sera from mice immunized 
with OMVs. The total amount of anti-LPS (a) or -OMP (b) IgG in the sera obtained from mice immunized 
intranasally with OMVs, the total amount of anti-LPS (c) or -OMP (d) IgG in the sera obtained from mice 
immunized intraperitoneally with OMVs, and the total amount of S-IgA that was specific for LPS (e) or for 
OMPs (f) were measured using quantitative ELISA. Each group consisted of 10 (control) or 12 (vaccinated) 
mice. The mice were immunized with OMVs that were derived from S. Typhimurium and then boosted at week 
5. Samples were collected at 4 weeks and 8 weeks after the first immunization. PBS-vaccinated mice served as 
the control group. The data shown represent the concentration of IgG or S-IgA antibodies in samples obtained 
from mice and are shown according to standard curves.
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levels than the control group (P < 0.05) at all time points (Fig. 3a–d). Furthermore, intraperitoneal immuniza-
tion induced higher anti-LPS and anti-OMP IgG production than intranasal immunization despite the fact that 
the dose used for intraperitoneal immunizations was one-fourth of the dose used for intranasal immunizations 
(Fig. 3a–d).
We also detected the levels of secretory IgA (S-IgA) antibodies in vaginal washes that were collected from 
the mice immunized with OMVs. At 8 weeks after immunization, the anti-LPS or anti-OMP S-IgA levels in the 
samples obtained from mice that were intranasally immunized with OMVs were significantly higher than the 
control group (P < 0.05) (Fig. 3e,f). No S-IgA antibodies against either LPS or OMPs were detected in the vaginal 
secretions obtained from the mice intraperitoneally immunized at 8 weeks (data not shown).
The concentrations of antibody isotypes against OMPs, including IgG1 and IgG2a, were also measured by quan-
titative ELISA. The data showed that OMVs, administered with intranasal route, induced Th1-biased immune 
Figure 4. Serum IgG1 and IgG2a responses in intranasally (a) and intraperitoneally (b) immunized and control 
mice. Outer membrane proteins (OMPs) as the coated immunogen. The data represented ELISA results 
determining the concentration of IgG1 and IgG2a subclass antibody to OMPs in the serum of mice immunized 
by intranasal or intraperitoneal route with flagellin-deficient OMVs. Each group has 10 or 12 mice. Mice were 
boosted at week 5 and blood samples were collected on 4 weeks and 8 weeks after first immunization.  
PBS-vaccinated mice were in the control group. The error bars represented variations between triplicate wells.
Figure 5. Survival in vaccinated mice after oral challenge with wild-type S. Typhimurium. Intranasal  
(a) and intraperitoneal (b) immunization with OMVs derived from S. Typhimurium flagellin-deficient 
mutants provided protection against oral challenge with wild-type S. Typhimurium in BALB/c mice. In total, 
10 (control) or 12 (vaccinated) mice per group were immunized twice at 4-week intervals with the indicated 
OMVs. The mice were challenged with 109 CFU of S. Typhimurium at 5 weeks after the boost immunization. 
Mortality was monitored for 3 weeks after challenge. The numbers in parentheses refer to the number of 
surviving mice and the total number of mice per group. All vaccine groups were significantly different from the 
PBS control group (P < 0.01).
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responses, as reflected by the significantly higher IgG2a production (Fig. 4a). This effect was independent of the 
immunization route; however, compared to intranasal immunization, intraperitoneal immunization induced a 
trend towards balanced immune responses of IgG1 and IgG2a (Fig. 4b).
Protection against virulent S. Typhimurium challenge. Immunized mice were challenged via the oral 
route with 109 CFU (2,000 × LD50) of the wild-type S. Typhimurium at 5 weeks after the booster immunization. 
Immunization with non-flagellin OMVs, administered either intranasally or intraperitoneally, provided 100% 
protection against oral S. Typhimurium challenge (Fig. 5). These results were significantly better than the survival 
rates in the PBS-immunized group (P < 0.05), all of which succumbed to challenge with the wild-type Salmonella 
within 12 days (Fig. 5).
Evaluation of cross-reactive immune responses and protection against heterologous 
Salmonella. To investigate the ability of OMVs to induce cross-reactive immune responses against heter-
ologous Salmonella, cross-reactive antibodies were evaluated using quantitative ELISA against OMPs that were 
Figure 6. Cross-reactivity of OMVs derived from flagellin-deficient S. Typhimurium mutant strain. 
Cross-reactivity of IgG in sera obtained from intranasally (a) or intraperitoneally (b) immunized mice against 
OMPs from other serotypes of Salmonella, including S. Choleraesuis and S. Enteritidis, to analyse OMV-
induced cross-protection. Each vaccinated group consisted of 12 mice, and the PBS group consisted of 10 mice. 
The cross-reactivity data represent the exact concentration of total IgG antibodies in the sera, as quantified 
using the corresponding standard curve using individual sera obtained from mice immunized intranasally 
or intraperitoneally with OMVs derived from S. Typhimurium. The error bars represent variations between 
triplicate wells. Competitive ELISA to determine the cross-reactivity of OMVs derived from flagellin-deficient 
mutant against heterologous Salmonella. OMPs isolated from S. Typhimurium were incubated into plates as 
coating antigen. OMPs from S. Choleraesuis, S. Enteritidis or S. Typhimurium (control) as the competitive 
antigen diluted from 1/10 to 1/ 7,290 were incubated in wells. The sera were obtained from mice (n = 10 or 12) 
immunized intranasally (c) or intraperitoneally (d) with OMVs at 8 weeks after the first immunization. The 
error bars represent variations from triplicate wells. P < 0.05 compared to the group of S. Typhimurium OMPs 
as the competitive antigen.
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isolated from S. Choleraesuis and S. Enteritidis. The flagellin-deficient OMVs that were administered either intra-
nasally or intraperitoneally elicited significantly robust IgG levels against OMPs derived from the two Salmonella 
serovars compared with the control group (P < 0.05) (Fig. 6a,b). Moreover, the OMVs administered either intra-
nasally or intraperitoneally induced higher IgG levels against the OMPs that were isolated from S. Choleraesuis 
than the levels against OMPs from S. Enteritidis (Fig. 6a,b). Furthermore, the competitive ELISA results further 
proved the cross-reactivity of non-flagellin OMVs against OMPs isolated from heterologous Salmonella serovars, 
and the cross-reactivity of non-flagellin OMVs against S. Choleraesuis OMPs was significantly higher these 
OMVs against OMPs from S. Enteritidis (P < 0.05) (Fig. 6c,d).
To examine the cross-protective ability of OMVs against other serotypes of Salmonella infection, immunized 
mice were orally challenged with 107 CFU of S. Choleraesuis (~100 × LD50) or S. Enteritidis (~100 × LD50) at 5 
weeks after the booster immunization. The flagellin-deficient OMVs that were administered either intranasally or 
intraperitoneally afforded 100% protection against S. Choleraesuis challenge (Fig. 7a,c). However, immunization 
with the non-flagellin OMVs provided 75% protection when mice were challenged with S. Enteritidis, and there 
was lower than the protective capacity conferred against wild-type S. Typhimurium (Figs 5 and 7b,d).
Discussion
Compared to live attenuated vaccine candidates, OMVs provide several potential advantages, including a lack of 
replication, better safety, higher immunogenicity and intrinsic adjuvant effects that are provided by LPS, OMPs 
and other immune-stimulating molecules11,38. It is therefore of particular interest to develop subunit vaccines that 
are based on OMVs. For example, OMVs from Neisseria lactamica, Pseudomonas aeruginosa, Vibrio cholerae and 
Clostridium perfringens have been evaluated to determine their protective efficacy against the respective bacterial 
infections9,10,15,39, and one OMV-based vaccine has been licensed in Europe for the prevention of N. meningitidis 
infection in individuals over 2 months old14. OMVs obtained from S. Typhimurium induce protective immune 
responses and have been used as carriers to deliver antigens from other pathogens13,40. The major components of 
OMVs isolated from Salmonella are OMPs, which confer protection against lethal challenge with homologous 
Salmonella in mice41,42. It is therefore worthwhile to investigate the ability of OMVs to induce protective immu-
nity against heterologous Salmonella serotypes.
Figure 7. Cross-protection of OMVs derived from flagellin-deficient S. Typhimurium mutant strain. 
Immunized mice were challenged orally with 107 CFU (~100-fold LD50) or 107 CFU (~100-fold LD50) of wild-
type S. Choleraesuis or S. Enteritidis, respectively. Mortality was monitored for 3 weeks after challenge.  
(a) Survival was followed in mice that were intranasally immunized using OMVs and subsequently submitted 
to by S. Choleraesuis challenge. (b) Survival was followed in mice that were intranasally immunized with 
OMVs and subsequently submitted to S. Enteritidis challenge. (c) Survival was followed in mice that were 
intraperitoneally immunized with OMVs and then submitted S. Choleraesuis challenge. (d) Survival was 
followed in mice that were intraperitoneally immunized with OMVs and then submitted to S. Enteritidis 
challenge. All vaccine groups were significantly different from the PBS control group (P < 0.01).
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Flagellin is highly immunogenic antigen capable of conferring protection against Salmonella infection. 
Both FliC and FljB flagellin proteins have a conserved region at the terminal ends essential for the assembly of 
the filament, and a variable central region accounting for antigenic variation with 114 H antigens presence in 
Salmonella18,43,44. While most of flagellin proteins are called FliC or FljB, but they don’t share the same antigenic 
determinants. For instance, FliC of S. Typhimurium possesses “i” H antigen, but FliC of S. Enteritidis has “g, m” 
H antigen45. These flagellins possessing distinct H antigen could not provide cross-protection against infection of 
heterologous Salmonella. And we observed a large amount of flagellin in the OMVs derived from the wild-type 
Salmonella (Fig. 1 and Fig. S1). These flagellin filaments in the OMVs may interfere with the immunogenicity of 
OMP and induce excessive pro-inflammatory responses16,46. Therefore, to develop a vaccine to confer broad pro-
tection against diverse Salmonella infection, the flagellin-deficient mutants were constructed by deletion of both 
the fliC and fljB genes. The ultrastructure of the OMVs that were obtained from S. Typhimurium was analysed 
using cryo-EM, and the results indicated the OMV sizes ranging from 20 to 250 nm (Fig. 1)47.
To develop an ideal, highly efficient vaccine for preventing Salmonella infection, both mucosal, systemic and 
cellular immunity should be considered48. Therefore, in this study we assessed mucosal and systemic immuno-
genicity of OMVs from flagellin-deficient S. Typhimurium when intranasally or intraperitoneally administered 
to mice. Consistent with previous studies13,39, mice intranasally immunized with OMVs showed high concentra-
tions of secretory IgA in vaginal washes (Fig. 3), indicating that intranasal administration elicited robust mucosal 
immune responses, and flagellin-deficient OMVs may be a good candidate vaccine to induce strong mucosal 
immunity. We also observed that significantly higher levels of IgG were elicited against the OMPs in the mice 
immunized with OMVs by intraperitoneal route than the levels of IgG in the mice immunized by intranasal 
route despite that the dose of OMVs used for intraperitoneal immunizations was one-fourth of the dose of intra-
nasal immunizations (Fig. 3a–d), the reason may probably rely on the facts that intraperitoneal immunization 
of Salmonella OMVs could more easily stimulate macrophage and dendritic cells and enhance production of 
pro-inflammatory mediators, thereby promoting the adaptive immunity49–51. We used a dose of 20 μ g OMV for 
intranasal administration because high doses of antigen are required to either reach the intestinal tract or deliv-
ered directly by the posterior cervical lymph nodes52. Many studies have used even higher doses (> 25 μ g) of 
Salmonella-derived OMVs to immunize mice7,13. Consistent with previous studies showing that recombinant, 
bacterially derived OMVs have potential as a platform to induce a Th1-biased immune response53,54, immunity 
induced by intranasally administered OMVs resulted in a predominant Th1 response, while OMVs delivered 
by the intraperitoneal route induced a more balanced Th1/Th2 response (Fig. 4). Despite these subtle differ-
ences, both intranasal and intraperitoneal immunization routes conferred complete protection against wild-type 
S. Typhimurium challenge (Fig. 5). While it is generally believed that a Th1-dominated immune response is 
critical to achieve a protective immune response against Salmonella infection in mice55–59, mucosal immunity 
represented by production of secretary IgA on the mucosal surface is also considered to play an important role in 
preventing Salmonella colonization in the thick mucus layer of the intestinal epithelium60–62. Moreover, a previ-
ous study showed that intraperitoneal immunization with high doses (25 μ g or more) of OMVs could represent 
a safety risk63. Therefore, intranasal immunization might be a more suitable strategy for vaccination with OMVs.
In this study, three Salmonella serotypes, which were isolated from commonly infected animals, were selected 
to evaluate the cross-protection conferred by OMVs. The results showed that OMVs derived from our Δ fliC 
ΔfljB mutant clearly induced the production of cross-reactive antibodies to OMPs from other Salmonella serovars 
(Fig. 6). The protective efficacy of the non-flagellin OMVs correlated well with the levels of antibodies that they 
induced (Figs 6 and 7). Mice immunized intranasally or intraperitoneally exhibited 100% protection follow-
ing challenge with wild-type S. Choleraesuis, indicating that flagellin-deficient OMVs may be an advantageous, 
broadly protective vaccine that can prevent multiple types of Salmonella infections. At this point, it is not clear 
that the observed cross-protection can be attributed to the conserved OMPs or to other conserved antigens that 
are shared among these three Salmonella serovars, such as the LPS core oligosaccharide moiety that is possessed 
by all Salmonella42. Future research efforts should be directed towards up-regulating conserved OMPs by truncat-
ing the length of LPS from the core of the O-antigen unit, reducing endotoxic activity and increasing production 
of OMVs via the genetic engineering of Salmonella strains.
In summary, our study demonstrated that deletion of flagellin did not affect OMV production as reflected by 
an assay of LPS and proteins as well as by cryo-EM evaluation and LC-MS/MS analysis. Vaccination of mice using 
non-flagellin OMVs protected against challenge with Salmonella and the use of flagellin-negative OMVs further 
allowed for developing multi-serotype protective vaccines. These results provide a new platform to deliver other 
antigens from other pathogens and to develop broad-spectrum vaccines.
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